A proteolysis targeting chimera (PROTAC) is a heterobifunctional molecule containing two small molecule-binding ligands joined together by a linker.
One of the small molecule ligands is designed to bind disease target protein in the cell whilst the other binds with high affinity to an E3 ligase. In the cell, the PROTAC molecule seeks out and selectively binds to the disease target protein of interest and is then able to recruit a specific E3 ligase to form a ternary complex, holding both the disease target protein and the E3 ligase in close proximity. The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex which is subsequently able to ubiquinate the target protein. E3 can then recruit additional E2 molecules resulting in poly-ubiquitination of the target protein and flagging it for degradation. The PROTAC molecule dissociates from the target protein and initiates another catalytic cycle leaving the poly-ubiquinated target protein to be degraded by the proteasome. This unique mode of action, which leads to depletion of disease target proteins from the cell, can drive distinct changes in cellular activity.
AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. Be inspired by the possibilities of science to make a difference and discover what you can do.
Partner with us
We know that innovation doesn’t happen in isolation, so we partner with others to access the best science and contribute complementary technologies, know-how and molecules.
Learn about us
Our IMED Biotech unit is committed to driving scientific advances in small molecules, oligonucleotides and other emerging technology platforms to push the boundaries of medical science.